Physician profile

Kelsey Stokes

Physician Assistant · Langhorne, PA

NPI 1376145607

$288.20

in general payments reported to CMS, 2019-2025

9 companies · $13.59 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$188.65

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $121.46 2023-2025 Integra, Integra Dermal Regeneration Template, Surgimend
Cumberland Pharmaceuticals, INC. $35.09 2021
Abbvie INC. $28.33 2023
Acera Surgical, INC. $21.58 2024 Restrata Wound Matrix
Sientra, INC. $18.30 2022
Resmed Corp $17.28 2023
Mylan Pharmaceuticals INC. $16.85 2022
Smith+Nephew, INC. $14.94 2022
Aroa Biosurgery Incorporated $14.37 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kelsey Stokes

$288.20

in general payments reported 2019-2025

Years
2021-2025
Top company
Integra Lifesciences Corporation

https://glasscript.com/doctor/10759213/kelsey-stokes

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.